On September 7, 2005, FDA announced the availability of a draft guidance, entitled “How to Comply with the Pediatric Research Equity Act,” providing sponsors with a number of recommendations regarding how the pediatric study requirements of the Pediatric Research Equity Act (PREA) should be interpreted.
PREA was enacted by Congress on December 3, 2003. It requires pharmaceutical companies to conduct pediatric studies of certain drugs and biological products. According to the draft guidance, “PREA is the most recent of more than a decade of legislative and regulatory attempts to address the lack of pediatric use information in drug product labeling.”
The pediatric assessment is made up of data from pediatric studies using appropriate formulations for each age group. This is done in order to:
Unless a deferral or waiver has been granted, PREA states that the pediatric assessment must be submitted at the time of the application’s submission.
The type of data that must be submitted under PREA is dependent on a number of factors, including:
According to its draft guidance, FDA states that “applicants should contact the appropriate review division to discuss the types of pediatric studies needed to complete their pediatric assessments.”
A pediatric plan does the following:
According to the draft guidance, FDA encourages all applicants to submit their pediatric plans to the Agency as soon as possible in the drug development process. In addition, applicants are also advised to discuss these plans with FDA at critical points in the development process.
For products intended for life-threatening or severely debilitating illnesses, applicants are encouraged to discuss the pediatric plan at the Pre-IND Meeting and End-of- Phase 1 (EOP1) meetings. This will allow the Agency to provide its best judgement on whether the pediatric studies will be required under PREA, and, if so, whether the submission will be deferred until after approval.
For products not intended for life-threatening or severely debilitating illnesses, FDA recommends that applicants submit and discuss the pediatric plan no later than the End-of-Phase 2 (EOP2) meeting. At this point, the review division will provide its best judgement regarding:
The FDA states that the appropriate age ranges to be studied may vary depending on the product, the manifestation of the disease in various age groups, and the ability to measure the response to therapy. However, in general, the pediatric population includes patients age birth to 16 years of age, including age groups often referred to as neonates, infants, children, and adolescents.
PREA states that all applicants “must submit requests for approval of the pediatric formulation used in their pediatric studies, and failure to submit such a request may render the product misbranded.” According to its draft guidance, FDA interprets ‘request for approval of a pediatric formulation’ to mean that an application must be submitted for any formulation used in the conduct of pediatric studies that has not been previously approved. Furthermore, it may also be necessary for applicants to develop the pediatric formulation before the pediatric clinical trial is initiated.
It is possible for FDA to waive the requirement for pediatric studies in certain age groups requiring a pediatric formulation if the applicant is able to demonstrate that it has made reasonable attempts and failed to produce the formulation necessary for that age group. However, this exception is only applicable to the pediatric groups requiring that specific formulation. This partial waiver generally applies only to situations where “unusually difficult technological problems prevented the development of a pediatric formulation.”
In the draft guidance, FDA states that pediatric studies for drugs that are conducted under an IND are subject to all of the rules governing INDs. These include:
In general, when submitted as a part of an application or supplement to an application, the content and format of the study reports must meet the relevant requirements for submission.
Based on established criteria, PREA grants FDA with the authority to waive or defer the pediatric assessment requirement for some or all pediatric age groups.
FDA can grant full or partial waivers, and they can be made on the Agency’s initiative or at the request of the applicant.
According to the draft guidance, a full waiver will be granted if FDA finds one or more of the following:
The Agency will grant a partial waiver if the applicant certifies and FDA finds evidence of one or more of the following:
Waivers that are agreed to at the EOP2 meeting will be documented in the meeting minutes, stating whether a full or partial waiver has been granted. Decisions to waive the pediatric assessment requirement that are made early can be reconsidered by the Agency at any time. “A waiver decision becomes final once issued in the approval letter for an NDA, BLA, or supplement.”
A deferral does not exempt a sponsor from submitting the required pediatric assessment, rather it simply permits the applicant to submit the assessment after the submission of the NDA, BLA, or supplemental NDA/BLA. Like waivers, deferrals can be made on FDA’s initiative or at the request of the sponsor.
The timing for the submission of some or all of the required pediatric studies may be deferred if FDA finds one or more of the following:
In order to obtain a deferral, sponsors must submit certification for the reason(s) for deferring the assessments, a description of the planned or ongoing studies, and evidence that the studies are being conducted or will be conducted with due diligence at the earliest possible time.
Deferral decisions are made on a case-by-case basis, and according to a number of considerations that help FDA determine whether and how long to defer submission of the pediatric assessment.
It is extremely important that sponsors are in compliance with all of PREA’s requirements. According to FDA’s draft guidance, “if a pediatric assessment or a request for approval of a pediatric formulation is not submitted by an applicant in accordance with the statutory requirements, the drug or biological product may be considered misbranded solely because of that failure and subject to relevant enforcement action.”
Navigating the requirements of PREA can be tricky. With so many options and loopholes, it is important to ensure that you are headed in the right direction and on the path to approval. We can help you do this. We have a 33-year track record of helping our clients receive successful interactions with FDA can help ensure compliance with all of PREA’s requirements and get you through FDA as quickly and smoothly as possible. To learn more about our services and how we can help you, contact us today.
December 16, 2016
During the development phase of a new drug, great pains are taken to characterize the molecule and to run a myriad of laboratory and animal tests to determine the product attributes, toxicology...
December 16, 2016
So what’s all the hub-bub about Digital Health? Is it really as big as they say? Is it just a fad? Is it all hype? Well, my answer is yes to all of the above. As with all major new technologies and...
December 16, 2016
The commissioning process is defined as "a quality-focused process for enhancing the delivery of a project. The process focuses upon verifying and documenting that all of the commissioned systems and...